AMEX · Biotechnology

PTHS (PTHS) Stock

$27.59 +6.44% AMEX: PTHS Healthcare

Valuation

MetricValue
Price$27.59
Market Cap$17.89M
P/E Ratio-1.18
P/B Ratio0.45
P/S Ratio0.63
EPS (TTM)$-23.04
52-Week High$54.29
52-Week Low$11.20
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-110.26%
ROA-33.08%
ROCE-84.21%
Gross Margin-188.24%
Operating Margin-188.24%
Net Margin-1.86%
Debt/Equity1.51
Current Ratio2.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$17.0M
Operating Profit$-1.0M$-2.0M$-7.0M$-8.0M$-32.0M
Net Profit$-1.0M$-2.0M$-7.0M$-8.0M$-43.0M
EPS$-1.00$-4.26$-12.80$-13.54$-23.04
Op Margin————-193.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets—$0$0$1.0M$130.0M
Total Liabilities—$4.0M$7.0M$4.0M$92.0M
Cash—$0$0$1.0M$18.0M
Borrowings$0$1.0M$1.0M$2.0M$35.0M

Latest News

Pelthos Therapeutics Added to Russell 3000E Growth, Microcap Indexes MT Newswires · Jun 30, 2026 Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes GlobeNewswire · Jun 30, 2026 Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference GlobeNewswire · May 28, 2026 Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary Moby · May 15, 2026 Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... GuruFocus.com · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow—$-2.0M$-1.0M$-6.0M$-23.0M
Investing Cash Flow—$0$0$0$-5.0M
Financing Cash Flow—$1.0M$0$0$0
Net Cash Flow—$0$0$0$18.0M
Free Cash Flow$0$-2.0M$-1.0M$-6.0M$-23.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-201.22%
Quick Ratio1.83
Interest Coverage-10.67
Return 1Y28.73%
Return 3Y—
Return 5Y—

Ownership

Insiders Held53.77%
Institutions Held35.57%
Institutions Float Held76.95%
Institutional HolderSharesReport Date
Murchinson Ltd.296,3142026-03-31
Ikarian Capital, LLC256,5982026-03-31
Vanguard Capital Management LLC93,0932026-03-31
Boothbay Fund Management, LLC81,8582026-03-31
J. Goldman & Co., L.P.50,4152026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CASICASI Pharmaceuticals, Inc. $0.15 +3.08% -0.07 $2.33M 0.00%
CING $4.52 -2.59% -1.08 $25.34M 0.00%
CLSDClearside Biomedical, Inc. $0.41 +0.00% -0.11 $2.15M 0.00%
ENLV $2.12 -5.36% 0.03 $35.68M 0.00%
KAPA $0.30 -3.20% -1.70 $6.42M 0.00%

About PTHS

PTHS is led by CEO Scott Plesha, employs 4 people, headquartered in US, publicly traded since 2025.

PTHS stock trades at $27.59 with a market capitalization of $17.89M. The stock is valued at a price-to-earnings (P/E) ratio of -1.18, price-to-book of 0.45, price-to-sales of 0.63. Over the past 52 weeks the stock has ranged between $11.20 and $54.29, and currently trades 49.2% below its 52-week high.

On profitability, PTHS generates a return on equity (ROE) of -110.26%, return on capital employed of -84.21%, an operating margin of -188.24%, a net profit margin of -1.86%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides